You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME

Gabapentin May Effectively Treat Hot Flashes

  • Authors: News Author: Laurie Barclay, MD
    CME Author: Laurie Barclay, MD
  • CME Released: 3/10/2008
  • THIS ACTIVITY HAS EXPIRED FOR CREDIT
  • Valid for credit through: 3/10/2009
Start Activity


Target Audience and Goal Statement

This article is intended for primary care clinicians, gynecologists, and other specialists who care for patients with menopausal hot flashes.

The goal of this activity is to provide medical news to primary care clinicians and other healthcare professionals in order to enhance patient care.

Upon completion of this activity, participants will be able to:

  1. Describe the efficacy of gabapentin at 900 mg/day for hot flashes in women who entered menopause naturally.
  2. Describe the tolerability of gabapentin for this indication.


Disclosures

As an organization accredited by the ACCME, Medscape, LLC requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.


Author(s)

  • Laurie Barclay, MD

    Laurie Barclay, MD, is a freelance reviewer and writer for Medscape.

    Disclosures

    Disclosure: Laurie Barclay, MD, has disclosed no relevant financial relationships.

Editor(s)

  • Brande Nicole Martin

    Brande Nicole Martin is the News CME editor for Medscape Medical News.

    Disclosures

    Disclosure: Brande Nicole Martin has disclosed no relevant financial information.

CME Author(s)

  • Laurie Barclay, MD

    Freelance reviewer and writer for Medscape

    Disclosures

    Disclosure: Laurie Barclay, MD, has disclosed no relevant financial relationships.


Accreditation Statements

    For Physicians

  • Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Medscape, LLC designates this educational activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™ . Physicians should only claim credit commensurate with the extent of their participation in the activity. Medscape Medical News has been reviewed and is acceptable for up to 300 Prescribed credits by the American Academy of Family Physicians. AAFP accreditation begins 09/01/07. Term of approval is for 1 year from this date. This activity is approved for 0.25 Prescribed credits. Credit may be claimed for 1 year from the date of this activity. AAFP credit is subject to change based on topic selection throughout the accreditation year.


    AAFP Accreditation Questions

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. Medscape encourages you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 5 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

CME

Gabapentin May Effectively Treat Hot Flashes

Authors: News Author: Laurie Barclay, MD CME Author: Laurie Barclay, MDFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME Released: 3/10/2008

Valid for credit through: 3/10/2009

processing....

March 10, 2008 — Gabapentin at 900 mg/day was effective in treating hot flashes, according to the results of a randomized, double-blind, controlled trial published in the March issue of Menopause.

"Gabapentin, a γ-aminobutyric acid, has been shown to reduce hot flashes in breast cancer patients, in women with chemically and/or surgically induced menopause, and in a small sample of women in natural menopause," write Debra A. Butt, MSc, MD, CCFP, from the University of Toronto in Toronto, Ontario, Canada, and colleagues. "Despite the promising evidence, gabapentin has not been adequately studied in postmenopausal women who enter menopause naturally."

The goal of this study was to compare the effectiveness and tolerability of gabapentin vs placebo for the treatment of hot flashes in women who enter menopause naturally.

Between March 2004 and April 2006, this study took place in the community and primary care settings across the Greater Toronto Area. Eligibility criteria were natural menopause, ages 45 to 65 years, with at least 14 hot flashes per week.

Of 200 eligible women, 197 were randomized to receive gabapentin 300-mg oral capsules or placebo 3 times daily for 4 weeks, and 193 (98%) completed the study. The main endpoint was the mean percentage change from baseline to week 4 in daily hot flash score, which was calculated from the participants' diaries. Secondary endpoints included changes in weekly mean hot flash scores and frequencies, quality of life, and adverse events. Analysis was by intent-to-treat.

From baseline to week 4, hot flash scores decreased by 51% (95% confidence interval [CI],
43% - 58%) in the gabapentin group and by 26% (95% CI, 18% - 35%) in the placebo group
(P < .001). In the gabapentin group, the Menopause-Specific Quality-of-Life vasomotor score decreased by 1.7 (95% CI, 1.3 - 2.1; P < .001).

Compared with the placebo group, the gabapentin group had a higher proportion of women who reported dizziness (18%), unsteadiness (14%), and drowsiness (12%) at week 1, but these symptoms decreased by week 2 and returned to baseline by week 4.

"Gabapentin at 900 mg/day is an effective and well-tolerated treatment for hot flashes," the study authors write.

Limitations of the study include lack of data beyond treatment week 4; dosage data available only for 900 mg/day, although a higher dose might have had a greater benefit in the reduction of hot flashes; and study population highly educated, predominantly white, and not ethnically diverse, limiting generalizability to other populations.

"Gabapentin seems to be an effective treatment for hot flashes with few side effects in women who are moderately affected by such symptoms in the general population," the study authors conclude. "Longer term studies of at least 3 months are needed to determine whether gabapentin continues to have a beneficial effect over a longer period."

The Physicians' Services Incorporated Foundation and the University of Toronto, Faculty of Medicine Dean's Fund funded this study. Pfizer, Inc, donated the gabapentin capsules. The study authors have disclosed no relevant financial relationships.

Menopause. 2008;15:310-318.

Clinical Context

Approximately half of postmenopausal women have hot flashes for 6 months to 5 years, or even longer, after natural menopause. In North America and Europe, only 1 approved treatment is available for hot flashes, namely hormone therapy (HT). Because risks associated with HT use have led to recommendations that HT be used at the lowest effective dose for the shortest duration possible, the number of HT prescriptions has markedly decreased.

Gabapentin has been shown to reduce hot flashes in women with breast cancer and in those with chemically or surgically induced menopause, or both, as well as in a small sample of women in natural menopause. Gabapentin seems to be a safe and well-tolerated drug, and it is currently licensed for use for the treatment of epilepsy. However, it has not been adequately studied in postmenopausal women who enter menopause naturally.

Study Highlights

  • The objective of this study was to compare the effectiveness and tolerability of gabapentin vs placebo for the treatment of hot flashes in women who enter menopause naturally.
  • Between March 2004 and April 2006, this study was conducted in the community and in primary care settings across the Greater Toronto Area.
  • Eligible women were in natural menopause, aged 45 to 65 years, with at least 14 hot flashes per week.
  • Of 200 eligible women, 197 were randomized to receive gabapentin 300-mg oral capsules or placebo 3 times daily for 4 weeks, and 193 (98%) completed the study.
  • The main endpoint was the mean percentage change from baseline to week 4 in daily hot flash score, which was calculated from the participants' diaries.
  • Secondary endpoints included changes in weekly mean hot flash scores and frequencies, quality of life, and adverse events.
  • Analysis was by intent-to-treat.
  • From baseline to week 4, hot flash scores decreased by 51% (95% CI, 43% - 58%) with the gabapentin group and by 26% (95% CI, 18% - 35%) with the placebo group (P < .001).
  • The frequency of hot flashes was an average of 8.5 per day at baseline, which decreased by week 4 to 4.5 per day with gabapentin vs 6.5 per day with placebo.
  • Analysis of the change in hot flash scores from baseline during each week of the study showed a rapid onset of action of gabapentin that was statistically significant in the first week and was maintained for 4 weeks.
  • In the gabapentin group, the Menopause-Specific Quality-of-Life vasomotor score decreased by 1.7 (95% CI, 1.3 - 2.1; P < .001).
  • Women in the gabapentin group experienced an improved quality of life after 4 weeks of treatment and said they would recommend this treatment to others.
  • Withdrawal rate from the study was 10%, primarily because of dizziness (18% in the gabapentin group at week 1).
  • Most withdrawals (10/14) occurred in the first week.
  • Compared with the placebo group, the gabapentin group also had a higher proportion of women who reported unsteadiness (14%) and drowsiness (12%) at week 1.
  • All adverse effects decreased by week 2 and returned to baseline by week 4.
  • Based on these findings, the investigators concluded that gabapentin at 900 mg/day was an effective and well-tolerated treatment of hot flashes in women who entered menopause naturally.
  • They also suggest that women who can tolerate the initiation of gabapentin would note a reduction in adverse effects after the first week. A lower initial dose and slower rate of titration may improve tolerability.
  • Limitations of the study include lack of data beyond week 4; dosage data available only for 900 mg/day, although a higher dose might have had a greater benefit; and study population highly educated and predominantly white, limiting generalizability to other ethnic groups.

Pearls for Practice

  • Gabapentin at 900 mg/day was an effective treatment of hot flashes in women who entered menopause naturally. Gabapentin at 900 mg/day was associated with a 51% reduction in hot flash scores from baseline to week 4. The average frequency of hot flashes decreased from 8.5 per day at baseline to 4.5 per day with gabapentin by week 4. Gabapentin had rapid onset of action that was evident in the first week and was maintained for 4 weeks.
  • Gabapentin at 900 mg/day was a well-tolerated treatment of hot flashes in women who entered menopause naturally. Withdrawal rate from the study was 10%, primarily because of dizziness (18% in the gabapentin group at week 1). Compared with the placebo group, the gabapentin group also had a higher proportion of women who reported unsteadiness and drowsiness at week 1. All adverse effects decreased by week 2 and returned to baseline by week 4.

CME Test

  • Print